Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5151MR)

This product GTTS-WQ5151MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5151MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ10464MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ15863MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ467MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ4020MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ11144MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10749MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ15188MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW